MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, DD1 5EH, UK.
Division of Molecular, Cell and Developmental Biology, School of Life Sciences, Wellcome Trust Biocentre, University of Dundee, Dundee, DD1 5EH, UK.
Sci Rep. 2024 Sep 6;14(1):20824. doi: 10.1038/s41598-024-71160-5.
Multiple studies have demonstrated that cancer cells with microsatellite instability (MSI) are intolerant to loss of the Werner syndrome helicase (WRN), whereas microsatellite-stable (MSS) cancer cells are not. Therefore, WRN represents a promising new synthetic lethal target for developing drugs to treat cancers with MSI. Given the uncertainty of how effective inhibitors of WRN activity will prove in clinical trials, and the likelihood of tumours developing resistance to WRN inhibitors, alternative strategies for impeding WRN function are needed. Proteolysis-targeting chimeras (PROTACs) are heterobifunctional small molecules that target specific proteins for degradation. Here, we engineered the WRN locus so that the gene product is fused to a bromodomain (Bd)-tag, enabling conditional WRN degradation with the AGB-1 PROTAC specific for the Bd-tag. Our data revealed that WRN degradation is highly toxic in MSI but not MSS cell lines. In MSI cells, WRN degradation caused G/M arrest, chromosome breakage and ATM kinase activation. We also describe a multi-colour cell-based platform for facile testing of selective toxicity in MSI versus MSS cell lines. Together, our data show that a degrader approach is a potentially powerful way of targeting WRN in MSI cancers and paves the way for the development of WRN-specific PROTAC compounds.
多项研究表明,具有微卫星不稳定性 (MSI) 的癌细胞对 Werner 综合征解旋酶 (WRN) 的缺失不耐受,而微卫星稳定 (MSS) 的癌细胞则不会。因此,WRN 代表了开发用于治疗 MSI 癌症的药物的有前途的新合成致死靶标。鉴于 WRN 活性抑制剂在临床试验中的有效性存在不确定性,以及肿瘤对 WRN 抑制剂产生耐药性的可能性,需要采用其他策略来阻碍 WRN 功能。蛋白水解靶向嵌合体 (PROTAC) 是靶向特定蛋白质进行降解的异双功能小分子。在这里,我们对 WRN 基因座进行了工程改造,使基因产物融合到溴结构域 (Bd)-标签上,从而可以使用 AGB-1 PROTAC 对 Bd 标签进行条件性 WRN 降解。我们的数据表明,WRN 降解在 MSI 中高度有毒,但在 MSS 细胞系中则不然。在 MSI 细胞中,WRN 降解导致 G/M 期阻滞、染色体断裂和 ATM 激酶激活。我们还描述了一种基于多色细胞的平台,用于方便地测试 MSI 与 MSS 细胞系之间的选择性毒性。总之,我们的数据表明,降解剂方法是靶向 MSI 癌症中 WRN 的一种潜在强大方法,并为开发 WRN 特异性 PROTAC 化合物铺平了道路。